
  
    
      
        Background_NNP
        In_IN the_DT United_NNP States_NNPS about_RB four_CD million_CD people_NNS have_VBP
        active_JJ peptic_JJ ulcers_NNS and_CC about_IN 350_CD ,_, 000_CD new_JJ cases_NNS are_VBP
        diagnosed_VBN each_DT year_NN ,_, and_CC approximately_RB 3000_CD deaths_NNS per_IN year_NN
        in_IN the_DT U_NNP ._. S_NNP ._. are_VBP due_JJ to_TO gastric_JJ ulcer_NN [_NN 1_CD ]_NN ._. The_DT primary_JJ
        therapeutic_JJ approach_NN to_TO gastric_JJ ulcer_NN remains_VBZ the_DT
        inhibition_NN of_IN gastric_JJ acid_NN secretion_NN to_TO produce_VB symptom_NN
        relief_NN ,_, acceleration_NN of_IN crater_NN healing_NN and_CC the_DT prevention_NN
        of_IN relapse_NN or_CC recurrence_NN [_NN 2_CD 3_CD ]_NN ,_, since_IN gastric_JJ ulcer_NN can_MD
        lead_VB to_TO hemorrhage_NN ,_, perforation_NN ,_, obstruction_NN and_CC death_NN [_NN 4_CD
        5_CD ]_NN ._.
        It_PRP is_VBZ established_VBN that_IN the_DT H_NNP +_NN ,_, K_NNP +_NN -_: ATPase_NNP ,_, or_CC proton_NN
        pump_NN ,_, participates_VBZ in_IN the_DT final_JJ step_NN of_IN acid_NN secretion_NN [_NN 6_CD
        7_CD ]_NN and_CC all_PDT the_DT peripheral_JJ parietal_NN cell_NN stimuli_NNS converge_NN
        to_TO activate_VBP it_PRP [_NN 7_CD ]_NN ._. Therefore_RB ,_, blocking_VBG the_DT final_JJ
        process_NN in_IN hydrogen_NN ion_NN secretion_NN reduces_VBZ acid_NN secretion_NN
        and_CC this_DT is_VBZ the_DT mechanism_NN of_IN action_NN of_IN the_DT substituted_VBN
        benzimidazole_NN agents_NNS known_VBN as_IN proton_NN pump_NN inhibitors_NNS (_( PPI_NNP )_) ._.
        Currently_RB ,_, five_CD PPIs_NNP are_VBP marketed_VBN :_: rabeprazole_NN ,_, omeprazole_NN ,_,
        esomeprazole_NN ,_, lansoprazole_NN and_CC pantoprazole_NN ,_, each_DT with_IN a_DT
        different_JJ pharmacokinetic_JJ profile_NN ,_, tissue_NN selectivity_NN ,_,
        binding_JJ specificity_NN and_CC potential_JJ to_TO interact_NN with_IN the_DT
        cytochrome_NN P_NN 450_CD enzyme_NN system_NN [_NN 8_CD 9_CD 10_CD ]_NN ._. For_IN example_NN ,_,
        rabeprazole_NN and_CC esomeprazole_NN achieve_VB more_RBR rapid_JJ and_CC
        profound_JJ inhibition_NN of_IN acid_NN secretion_NN than_IN do_VBP older_JJR agents_NNS
        [_NN 10_CD ]_NN ._. It_PRP is_VBZ unclear_JJ ,_, however_RB ,_, if_IN these_DT pharmacologic_JJ
        differences_NNS lead_VBP to_TO distinctions_NNS in_IN the_DT clinical_JJ efficacy_NN
        of_IN healing_VBG gastric_JJ ulcers_NNS and_CC controlling_VBG ulcer_NN symptoms_NNS ._.
        To_TO address_VB this_DT question_NN we_PRP undertook_VBD a_DT meta-analysis_JJ of_IN
        all_DT randomized_JJ clinical_JJ trials_NNS that_WDT compared_VBD at_IN least_JJS one_CD
        of_IN the_DT newer_JJR PPI_NNP with_IN either_DT ranitidine_NN or_CC placebo_NN ._.
      
      
        Methods_NNP
        
          Statistical_NNP analysis_NN
          The_DT healing_NN rate_NN ratio_NN (_( RR_NNP )_) was_VBD calculated_VBN for_IN each_DT
          trial_NN by_IN dividing_VBG the_DT healing_NN rate_NN of_IN the_DT PPI_NNP by_IN the_DT rate_NN
          with_IN the_DT comparator_NN at_IN the_DT specified_VBN time_NN point_NN ._.
          Chi-squares_NNP and_CC 95_CD %_NN confidence_NN intervals_NNS (_( CI_NNP )_) were_VBD
          calculated_VBN using_VBG the_DT exact_JJ method_NN described_VBN by_IN Miettinen_NNP
          [_NN 11_CD ]_NN ._.
          The_DT appropriateness_NN of_IN combining_VBG results_NNS from_IN
          individual_JJ studies_NNS was_VBD examined_VBN using_VBG the_DT Wald_NNP χ_NN 2_CD for_IN
          statistical_JJ homogeneity_NN ._. We_PRP considered_VBD a_DT 
          p_NN value_NN less_JJR than_IN 0_CD ._. 05_CD to_TO be_VB
          significant_JJ for_IN all_DT statistical_JJ tests_NNS ._. There_EX were_VBD no_DT
          adjustments_NNS for_IN multiple_JJ comparisons_NNS ._.
          As_IN there_EX was_VBD no_DT statistically_RB significant_JJ evidence_NN of_IN
          heterogeneity_NN ,_, the_DT healing_NN rates_NNS for_IN each_DT treatment_NN were_VBD
          pooled_VBN across_IN trials_NNS by_IN time_NN point_NN ._. Overall_RB healing_NN rates_NNS
          of_IN PPIs_NNP at_IN four_CD and_CC eight_CD weeks_NNS were_VBD estimated_VBN by_IN pooling_VBG
          the_DT rates_NNS for_IN the_DT recommended_VBN daily_JJ doses_NNS :_: 30_CD mg_NN /_NN d_SYM for_IN
          lansoprazole_NN ,_, 20_CD mg_NN /_NN d_SYM for_IN omeprazole_NN ,_, 40_CD mg_NN /_NN d_SYM for_IN
          pantoprazole_NN ._. Rabeprazole_NNP was_VBD pooled_VBN using_VBG dose_NN of_IN 20_CD
          mg_NN /_NN d_SYM at_IN three_CD and_CC six_CD weeks_NNS ._. Individual_JJ trial_NN results_NNS
          were_VBD weighted_JJ using_VBG the_DT inverse_NN of_IN the_DT variance_NN of_IN the_DT RR_NNP
          estimated_VBD for_IN each_DT trial_NN ._. The_DT overall_JJ RR_NNP was_VBD then_RB
          estimated_VBN by_IN dividing_VBG the_DT weighted_JJ average_NN healing_NN rates_NNS
          for_IN each_DT treatment_NN with_IN the_DT estimates_NNS for_IN placebo_NN ,_,
          ranitidine_NN or_CC omeprazole_NN ._. These_DT overall_JJ RR_NNP were_VBD assessed_VBN
          using_VBG the_DT Mantel-_NNP Haenszel_NNP χ_NN 2_CD test_NN and_CC 95_CD %_NN CI_NNP were_VBD
          calculated_VBN using_VBG the_DT exact_JJ method_NN [_NN 11_CD ]_NN ._.
          To_TO assess_VB the_DT possibility_NN of_IN publication_NN bias_NN ,_, the_DT RR_NNP
          point_NN estimates_NNS were_VBD plotted_VBD against_IN year_NN of_IN publication_NN
          and_CC sample_NN size_NN ._. To_TO identify_VB any_DT studies_NNS that_WDT exerted_VBN a_DT
          disproportionate_JJ influence_NN on_IN the_DT summary_NN treatment_NN
          effect_NN ,_, we_PRP deleted_VBN individual_JJ studies_NNS one_CD at_IN a_DT time_NN ._. To_TO
          investigate_VB the_DT possible_JJ consequences_NNS of_IN including_VBG
          abstracts_NNS for_IN which_WDT we_PRP could_MD not_RB obtain_VB full_JJ reports_NNS ,_, we_PRP
          excluded_VBD these_DT data_NNS in_IN secondary_JJ analyses_NNS ._.
        
      
      
        Results_NNS
        
          Clinical_NNP symptoms_NNS
          It_PRP was_VBD not_RB possible_JJ to_TO pool_NN these_DT results_NNS because_IN
          different_JJ symptoms_NNS were_VBD reported_VBN in_IN each_DT study_NN ,_, at_IN
          different_JJ time_NN points_NNS ,_, and_CC also_RB the_DT method_NN used_VBN to_TO
          collect_VB data_NNS varied_VBD (_( Table_NNP 2_LS )_) ._. However_RB ,_, individual_JJ trials_NNS
          showed_VBD more_JJR improvement_NN or_CC resolution_NN of_IN pain_NN ,_, day_NN pain_NN
          and_CC night_NN pain_NN was_VBD found_VBN with_IN the_DT new_JJ PPIs_NNP rabeprazole_NN ,_,
          pantoprazole_NN and_CC lansoprazole_NN compared_VBN to_TO omeprazole_NN ._. For_IN
          example_NN ,_, 82_CD %_NN of_IN patients_NNS with_IN pain_NN improved_VBN with_IN
          rabeprazole_NN compared_VBN to_TO 65_CD %_NN with_IN omeprazole_NN at_IN 6_CD weeks_NNS [_NN
          26_CD ]_NN (_( Table_NNP 2_LS )_) ._.
        
        
          Healing_NNP rates_NNS
          Healing_NNP data_NNS are_VBP presented_VBN for_IN the_DT intention-to-treat_JJ
          analyses_NNS as_IN similar_JJ results_NNS were_VBD obtained_VBN with_IN the_DT per_IN
          protocol_NN analysis_NN ._. For_IN lansoprazole_NN ,_, pantoprazole_NN and_CC
          omeprazole_NN the_DT results_NNS were_VBD reported_VBN at_IN four_CD and_CC eight_CD
          weeks_NNS and_CC the_DT rabeprazole_NN studies_NNS did_VBD so_RB at_IN three_CD and_CC six_CD
          weeks_NNS ._. Therefore_RB ,_, the_DT overall_JJ healing_NN rate_NN was_VBD obtained_VBN
          at_IN three_CD ,_, four_CD ,_, six_CD and_CC eight_CD weeks_NNS ._.
          Healing_NNP rates_NNS varied_VBD between_IN the_DT studies_NNS ,_, but_CC were_VBD
          consistently_RB lower_JJR with_IN placebo_NN treatment_NN ._. For_IN the_DT
          majority_NN of_IN patients_NNS receiving_VBG placebo_NN treatment_NN the_DT
          ulcer_NN did_VBD not_RB heal_VB during_IN the_DT course_NN of_IN the_DT trial_NN and_CC the_DT
          maximum_NN recorded_VBN as_IN healed_VBN was_VBD just_RB over_IN a_DT third_JJ of_IN the_DT
          patients_NNS (_( 39_CD %_NN )_) in_IN any_DT of_IN the_DT trials_NNS ._. Whilst_NNP higher_JJR
          healing_NN rates_NNS were_VBD observed_VBN after_IN treatment_NN with_IN
          ranitidine_NN by_IN the_DT end_NN of_IN the_DT trials_NNS the_DT ulcers_NNS remained_VBD
          for_IN at_IN least_JJS half_PDT the_DT patients_NNS (_( 52_CD %_NN )_) ._. In_IN contrast_NN ,_, by_IN the_DT
          end_NN of_IN the_DT trial_NN the_DT ulcers_NNS were_VBD healed_VBN in_IN at_IN least_JJS
          two-thirds_NNS of_IN the_DT patients_NNS receiving_VBG proton_NN pump_NN
          inhibitors_NNS (_( 67_CD %_NN )_) ._.
          As_IN would_MD be_VB expected_VBN ,_, when_WRB compared_VBN with_IN placebo_NN
          treatment_NN ,_, the_DT PPIs_NNP (_( lansoprazole_NN and_CC omeprazole_NN )_)
          improved_VBD the_DT pooled_VBN healing_NN RR_NNP at_IN each_DT time_NN point_NN ._. In_IN
          relation_NN to_TO ranitidine_NN ,_, the_DT pooled_VBN healing_NN RR_NNP of_IN PPIs_NNP
          (_( lansoprazole_NN ,_, omeprazole_NN and_CC pantoprazole_NN )_) was_VBD also_RB
          increased_VBN at_IN both_DT four_CD and_CC eight_CD weeks_NNS ._. There_EX were_VBD no_DT
          studies_NNS versus_CC rabeprazole_NN ._. The_DT healing_NN RR_NNP in_IN each_DT trial_NN
          of_IN the_DT newer_JJR PPIs_NNP was_VBD found_VBN to_TO be_VB comparable_JJ or_CC better_JJR
          than_IN omeprazole_NN at_IN each_DT time_NN point_NN (_( Figure_NN 1_LS )_) ._.
        
        
          Publication_NNP bias_NN
          The_DT healing_NN RR_NNP was_VBD plotted_VBD against_IN sample_NN size_NN but_CC
          there_EX was_VBD no_DT trend_NN with_IN increasing_VBG size_NN :_: small_JJ studies_NNS
          had_VBD healing_VBG RR_NNP similar_JJ to_TO large_JJ studies_NNS with_IN the_DT same_JJ
          comparator_NN (_( Figure_NN 2_LS )_) ._. There_EX was_VBD one_CD abstract_JJ [_NN 27_CD ]_NN with_IN
          data_NNS obtained_VBN at_IN 3_CD and_CC 6_CD weeks_NNS ,_, which_WDT is_VBZ not_RB
          included_VBN ._.
        
      
      
        Discussion_NNP
        In_IN the_DT absence_NN of_IN active_JJ treatment_NN ,_, the_DT majority_NN of_IN
        patients_NNS continued_VBD to_TO have_VB a_DT gastric_JJ ulcer_NN at_IN the_DT end_NN of_IN
        the_DT trial_NN ._. A_DT much_RB higher_JJR healing_NN rate_NN was_VBD observed_VBN when_WRB
        patients_NNS received_VBD treatment_NN with_IN a_DT PPI_NNP when_WRB compared_VBN to_TO
        either_CC a_DT placebo_NN or_CC ranitidine_NN ._. This_DT is_VBZ consistent_JJ with_IN the_DT
        results_NNS obtained_VBN for_IN treatment_NN with_IN PPIs_NNP when_WRB compared_VBN to_TO
        ranitidine_NN for_IN both_DT duodenal_JJ ulcers_NNS and_CC gastro_NN esophageal_NN
        reflux_NN disease_NN [_NN 2_CD 28_CD ]_NN ._. We_PRP also_RB found_VBD that_IN ,_, there_EX is_VBZ some_DT
        evidence_NN of_IN an_DT advantage_NN to_TO prescribing_VBG two_CD of_IN the_DT newer_JJR
        PPIs_NNP (_( lansoprazole_NN or_CC pantoprazole_NN )_) compared_VBN to_TO omeprazole_NN
        for_IN gastric_JJ ulcer_NN ,_, since_IN there_EX was_VBD a_DT 15_CD %_NN increase_NN in_IN
        healing_NN rates_NNS at_IN 4_CD weeks_NNS ._. In_IN addition_NN ,_, the_DT newer_JJR PPIs_NNP
        (_( rabeprazole_NN ,_, lansoprazole_NN and_CC pantoprazole_NN )_) have_VBP all_DT been_VBN
        show_NN to_TO produce_VB superior_JJ improvement_NN in_IN clinical_JJ symptoms_NNS
        compared_VBN to_TO omeprazole_NN at_IN both_DT 2_CD and_CC 4_CD weeks_NNS [_NN 24_CD 25_CD 26_CD ]_NN
        ._.
        Relatively_RB few_JJ randomized_JJ controlled_VBN clinical_JJ trials_NNS
        have_VBP been_VBN published_VBN on_IN the_DT efficacy_NN of_IN PPI_NNP for_IN treating_VBG
        gastric_JJ ulcers_NNS when_WRB compared_VBN with_IN gastro_NN esophageal_NN reflux_NN
        disease_NN or_CC with_IN duodenal_JJ ulcers_NNS [_NN 29_CD 30_CD ]_NN ._. This_DT could_MD be_VB
        due_JJ to_TO gastric_JJ ulcers_NNS being_VBG less_RBR frequently_RB diagnosed_VBN than_IN
        duodenal_JJ ulcer_NN [_NN 31_CD ]_NN ,_, or_CC the_DT importance_NN of_IN clinicians_NNS
        confirming_VBG a_DT differential_NN diagnosis_NN between_IN gastric_JJ ulcer_NN
        and_CC gastric_JJ cancer_NN ._. Some_DT authors_NNS have_VBP also_RB argued_VBN that_IN the_DT
        classification_NN of_IN gastric_JJ and_CC duodenal_JJ ulcers_NNS is_VBZ
        artificial_JJ ,_, since_IN ulcers_NNS could_MD be_VB driven_VBN distally_RB or_CC drawn_VBN
        proximally_RB across_IN the_DT arbitrary_JJ boundary_NN of_IN the_DT pylorus_JJ [_NN
        32_CD ]_NN ._. Furthermore_RB ,_, some_DT clinical_JJ assessments_NNS may_MD be_VB
        complicated_VBN as_IN 10_CD -_: 20_CD %_NN of_IN patients_NNS with_IN gastric_JJ ulcers_NNS also_RB
        have_VBP duodenal_JJ ulcers_NNS ._. However_RB ,_, given_VBN the_DT severity_NN of_IN the_DT
        symptoms_NNS generally_RB associated_VBN with_IN a_DT gastric_JJ ulcer_NN ,_, there_EX
        no_RB longer_RB appears_VBZ to_TO be_VB a_DT clear_JJ justification_NN for_IN
        continuing_VBG to_TO conduct_VB placebo-controlled_JJ trials_NNS in_IN these_DT
        patients_NNS ._.
        Recent_JJ observations_NNS have_VBP suggested_VBN that_IN the_DT duration_NN of_IN
        treatment_NN with_IN acid_NN secretory_NN inhibitors_NNS is_VBZ more_RBR important_JJ
        than_IN the_DT degree_NN of_IN acid_NN inhibition_NN per_IN 24_CD -_: hours_NNS [_NN 33_CD ]_NN ._. We_PRP
        could_MD not_RB test_VB the_DT long-term_JJ effect_NN of_IN PPIs_NNP on_IN ulcer_NN
        relapse_NN rates_NNS ,_, since_IN there_EX was_VBD not_RB enough_JJ information_NN
        published_VBN ._. More_JJR research_NN into_IN maintenance_NN therapy_NN is_VBZ
        clearly_RB required_VBN ,_, because_IN the_DT relative_JJ long-term_JJ efficacy_NN
        of_IN different_JJ treatments_NNS ,_, particularly_RB the_DT combination_NN of_IN
        PPIs_NNP with_IN antibiotics_NNS ,_, and_CC the_DT effect_NN of_IN dose_NN variation_NN on_IN
        the_DT relapse_NN and_CC complications_NNS from_IN gastric_JJ ulcers_NNS is_VBZ not_RB
        well_RB studied_VBN ._. Other_JJ factors_NNS known_VBN to_TO have_VB an_DT impact_NN on_IN
        gastric_JJ ulcer_NN healing_NN are_VBP smoking_VBG ;_: alcohol_NN and_CC ulcer_NN size_NN ,_,
        but_CC the_DT papers_NNS did_VBD not_RB report_VB the_DT healing_NN results_NNS for_IN these_DT
        subgroups_NNS of_IN patients_NNS or_CC by_IN those_DT variables_NNS ._. Unfortunately_RB ,_,
        the_DT researchers_NNS reported_VBD different_JJ clinical_JJ symptoms_NNS and_CC
        methods_NNS to_TO collect_VB the_DT data_NNS and_CC so_IN we_PRP could_MD not_RB pool_NN these_DT
        results_NNS ._.
      
      
        Conclusions_NNP
        This_DT study_NN suggests_VBZ that_IN the_DT first-line_JJ drug_NN therapy_NN for_IN
        patients_NNS diagnosed_VBN with_IN gastric_JJ ulcer_NN should_MD be_VB a_DT PPI_NNP ,_, in_IN
        preference_NN to_TO an_DT H_NNP 2_CD antagonist_NN ._. This_DT study_NN indicated_VBD that_WDT
        compared_VBD with_IN ranitidine_NN the_DT PPIs_NNP provide_VB faster_JJR onset_NN of_IN
        action_NN ,_, greater_JJR relief_NN of_IN symptoms_NNS and_CC increased_VBN healing_NN
        rates_NNS ._. However_RB ,_, there_EX is_VBZ also_RB clearly_RB a_DT need_NN for_IN additional_JJ
        studies_NNS to_TO determine_VB the_DT appropriate_JJ maintenance_NN doses_NNS and_CC
        understand_VB the_DT factors_NNS influencing_VBG healing_NN and_CC relapse_NN
        rates_NNS ._.
      
      
        Abbreviations_NNP
        PPI_NNP :_: Proton_NNP pump_VB inhibitor_NN
        H_NNP 2_CD A_DT :_: Histamine_NNP 
        2_CD receptor_NN antagonist_NN
        RR_NNP :_: Rate_NNP ratio_NN
        CI_NNP :_: Confidence_NN intervals_NNS
      
      
        Competing_VBG interests_NNS
        This_DT research_NN was_VBD supported_VBN in_IN part_NN by_IN an_DT unrestricted_JJ
        grant_NN from_IN Janssen_NNP Ortho_NNP Canada_NNP ._.
      
      
        Authors_NNP '_'' Contributions_NNP
        All_DT authors_NNS participated_VBD in_IN the_DT design_NN ,_, analyses_NNS ,_,
        editing_NN and_CC final_JJ approval_NN of_IN the_DT manuscript_NN ._.
      
    
  
